{"id":38029,"date":"2025-06-23T10:04:07","date_gmt":"2025-06-23T08:04:07","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=38029"},"modified":"2025-06-13T10:45:01","modified_gmt":"2025-06-13T08:45:01","slug":"antikoagulation-mit-faktor-xi-xia-inhibitoren-revolution-vorerst-gestoppt","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2025\/antikoagulation-mit-faktor-xi-xia-inhibitoren-revolution-vorerst-gestoppt","title":{"rendered":"Antikoagulation mit Faktor-XI\/XIa-Inhibitoren: Revolution (vorerst) gestoppt?"},"content":{"rendered":"<p>Gerinnungshemmende Arzneimittel sind unverzichtbar in der Pr\u00e4vention und Therapie arterieller und ven\u00f6ser Thrombosen und Thromboembolien. Da sie inh\u00e4rent das Blutungsrisiko erh\u00f6hen, muss bei jeder Verschreibung das individuelle Thrombose- und Blutungsrisiko abgewogen werden. Daran hat auch die Entwicklung der direkten oralen Antikoagulanzien (DOAK), die die Vitamin-K-Antagonisten (VKA) inzwischen in nahezu allen Indikationen ersetzt haben, nichts ge\u00e4ndert. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gerinnungshemmende Arzneimittel sind unverzichtbar in der Pr\u00e4vention und Therapie arterieller und ven\u00f6ser Thrombosen und Thromboembolien. Da sie inh\u00e4rent das Blutungsrisiko erh\u00f6hen, muss bei jeder Verschreibung das individuelle Thrombose- und Blutungsrisiko abgewogen werden. Daran hat auch die Entwicklung der direkten oralen Antikoagulanzien (DOAK), die die Vitamin-K-Antagonisten (VKA) inzwischen in nahezu allen Indikationen ersetzt haben, nichts ge\u00e4ndert. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[6214,185,684,137,60,6206,6213,6204,6205,68,6212,6209,6210,6215,6208,6207,6211,56,51,6203,181],"class_list":["post-38029","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abelacimab","tag-absolute-arrhythmie","tag-akutes-koronarsyndrom","tag-antikoagulanzien","tag-apoplektischer-insult","tag-asundexian","tag-azalea-timi-71-studie","tag-faktor-xi-inhibitoren","tag-faktor-xia-inhibitoren","tag-hirninfarkt","tag-librexia-acs-studie","tag-librexia-af-studie","tag-librexia-stroke-studie","tag-lilac-timi-76-studie","tag-milvexian","tag-oceanic-af-studie","tag-oceanic-stroke-studie","tag-schlaganfall","tag-thrombose","tag-time-studie","tag-vorhofflimmern"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=38029"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38029\/revisions"}],"predecessor-version":[{"id":38030,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38029\/revisions\/38030"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=38029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=38029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=38029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}